Maat Pharma SA (MAAT) - Total Assets
Based on the latest financial reports, Maat Pharma SA (MAAT) holds total assets worth €48.88 Million EUR (≈ $57.14 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Maat Pharma SA - Total Assets Trend (2017–2024)
This chart illustrates how Maat Pharma SA's total assets have evolved over time, based on quarterly financial data. Also see MAAT stock market capitalisation for the company's overall valuation and market capitalisation.
Maat Pharma SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Maat Pharma SA's total assets of €48.88 Million consist of 71.8% current assets and 28.2% non-current assets. Review MAAT total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €8.69 Million | 52.4% |
| Accounts Receivable | €1.51 Million | 3.9% |
| Inventory | €64.00K | 0.2% |
| Property, Plant & Equipment | €8.60 Million | 22.3% |
| Intangible Assets | €1.77 Million | 4.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Maat Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MAAT stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maat Pharma SA's current assets represent 71.8% of total assets in 2024, a decrease from 94.9% in 2017.
- Cash Position: Cash and equivalents constituted 52.4% of total assets in 2024, down from 79.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is cash and equivalents at 52.4% of total assets.
Maat Pharma SA Competitors by Total Assets
Key competitors of Maat Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Maat Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 2.76 | 2.40 |
| Quick Ratio | 2.21 | 2.75 | 2.40 |
| Cash Ratio | 0.00 | 0.92 | 0.00 |
| Working Capital | €19.53 Million | €25.93 Million | €3.42 Million |
Maat Pharma SA - Advanced Valuation Insights
This section examines the relationship between Maat Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.89 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | €38.50 Million |
| Market Capitalization | $35.73 Million USD |
Valuation Analysis
Near Book Valuation: The market values Maat Pharma SA's assets close to their book value (0.93x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Maat Pharma SA's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Maat Pharma SA (2017–2024)
The table below shows the annual total assets of Maat Pharma SA from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €38.50 Million ≈ $45.01 Million |
-10.32% |
| 2023-12-31 | €42.93 Million ≈ $50.19 Million |
-4.01% |
| 2022-12-31 | €44.73 Million ≈ $52.29 Million |
-9.50% |
| 2021-12-31 | €49.42 Million ≈ $57.78 Million |
+103.58% |
| 2020-12-31 | €24.28 Million ≈ $28.38 Million |
+197.14% |
| 2019-12-31 | €8.17 Million ≈ $9.55 Million |
+38.83% |
| 2018-12-31 | €5.88 Million ≈ $6.88 Million |
-36.46% |
| 2017-12-31 | €9.26 Million ≈ $10.83 Million |
-- |
About Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more